Assessment of therapeutic himor response using 99mTc- ethylenedicysteine-glucosamine

Cancer Biotherapy and Radiopharmaceuticals

Volumn 19, Issue 4, 2004, Pages 443-456

  Yang, David ^a   Yukihiro, Masashi ^a   Yu, Dong Fang ^a   Ito, Megumi ^a   Oh, Chang Sok ^a   Kohanim, Saady ^a   Azhdarinia, Ali ^a   Kim, Chang Guhn ^a   Bryant, Jerry ^a   Kim, E Edmund ^a   Podoloff, Donald ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

99mTc EC DG; Biodistribution; Imaging

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CISPLATIN; CYSTEINE ETHYL ESTER TC 99M; ETHYLENEDICYSTEINE GLUCOSAMINE TC 99M; FLUORODEOXYGLUCOSE F 18; GLUCOSAMINE; MESSENGER RNA; PACLITAXEL; UNCLASSIFIED DRUG; CYSTEINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; ETHYLENE DICYSTEINE; GLUCOSE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX; THYMIDINE;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTORADIOGRAPHY; CANCER CELL; CELL CYCLE; CONTROLLED STUDY; DOSIMETRY; DRUG DISTRIBUTION; DRUG EFFICACY; FLOW CYTOMETRY; GAMMA SCINTIGRAPHY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; TUMOR; TUMOR GROWTH; ANIMAL; CELL DIVISION; DRUG EFFECT; EXPERIMENTAL NEOPLASM; FEMALE; METABOLISM; PATHOLOGY; RADIOMETRY;

ANIMALS; APOPTOSIS; AUTORADIOGRAPHY; CELL CYCLE; CELL DIVISION; CYSTEINE; FEMALE; GLUCOSAMINE; GLUCOSE; MICE; NEOPLASMS, EXPERIMENTAL; ORGANOTECHNETIUM COMPOUNDS; RABBITS; RADIOMETRY; RADIOPHARMACEUTICALS; THYMIDINE;

EID: 4644251927     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2004.19.443     Document Type: Article

References (39)

1. 3H]thymidine, and gallium-67. J Nucl Med 1991; 32:2118.
2. Tjuvajev J, Muraki A, Ginos J, et al. Iododeoxyuridine uptake and retention as a measure of tumor growth. J Nucl Med 1993;34:1152.
3. Strauss LG, Conti PS. The application of PET in clinical oncology. J Nucl Med 1991;32:623.
4. Ohtsuki K, Akashi K, Aoka Y, et al. Technetium-99m HYNIC-Annexin V: A potential radiopharmaceutical for the in vivo detection of apoptosis. Eur J Nucl Med 1999;26:1251.
5. 99mTc Annexin V for in vivo imaging of apoptosis during cardiac allograft rejection. J Thorac Cardiovasc Surg 1998;116:844.
6. Van Nerom CG, Bormans GM, De Roo MJ, et al. First experience in healthy volunteers with technetium-99m L,L-ethylenedicysteine, a new renal imaging agent. Eur J Nucl Med 1993;20:738.
7. Canet EP, Casali C, Desenfant A, et al. Kinetic characterization of CMD-A2-Gd-DOTA as an intravascular contrast agent for myocardial perfusion measurement with MRI. Magn Reson Med 2000;43:403.
8. Laissy JP, Faraggi M, Leblahi R, et al. Functional evaluation of normal and ischemic kidney by means of gadolinium-DOTA enhanced TurboFLASH MR imaging: A preliminary comparison with 99Tc-MAG3 dynamic scintigraphy. Magn Reson Imaging 1994;12: w413.
9. Kao CH, ChangLai SP, Chieng PU, et al. Technetium-99m methoxyisobutylisonitrile chest imaging of small-cell lung carcinoma: Relation to patient prognosis and chemotherapy response-a preliminary report. Cancer 1998;83:64.
10. Wu HC, Chang CH, Lai MM, et al. Using Tc-99m DMSA renal cortex scan to detect renal damage in women with type 2 diabetes. J Diabetes Complications 2003;17:297.
11. Blondeau P, Berse C, Gravel D. Dimerization of an intermediate during the sodium in liquid ammonia reduction of L-thiazolidine-4-carboxylic acid. Can J Chem 1967;45:49.
12. Ratner S, Clarke HT. The action of formaldehyde upon cysteine. J Am Chem Soc 1937;59:200.
13. 99mTc- ethylenedicysteinefolate: A new tumor imaging agent. Synthesis, labeling, and evaluation in animals. Cancer Biother Radiopharm 1998;13:427.
14. 99mTc- ethylenedicysteine-colchicine for evaluation of antiangiogenic effects. Anti-Cancer Drugs 1999;10:685.
15. 99mTc-labeled metronidazole. Pharm Res 1999;16:743.
16. 99mTc-EC-Annexin V. Cancer Biother Radiopharm 2001;16:73.
17. 99mTc-EC-endostatin. Cancer Biother Radiopharm 2002;17:233.
18. Schechter NR, Yang DJ, Azhdarinia A, et al. Assessment of epidermal growth factor receptor with 99mTc-ethylenedicysteine-C225 monoclonal antibody. Anti-Cancer Drugs 2003;14:49.
19. 99mTc ECDG targeted at the multifunctional glucose transport system: Feasibility study with rodents. Radiology 2003;226:465.
20. 99mTc-labeled metronidazole. Stroke 2003;34:982.
21. Anderson CJ, John CS, Li YJ, et al. N,N′-ethylene-di-L-cysteine (EC) complexes of Ga(III) and In(III): Molecular modeling, thermodynamic stability, and in vivo studies. Nucl Med Biol 1995;22:165.
22. Das T, Banerjee S, Samuel G, et al. [(186/18S)Re] rhenium-ethylene dicysteine (Re-Ec): Preparation and evaluation for possible use in endovascular brachytherapy. Nucl Med Biol 2000;27:189.
23. Li Y, Martell AE, Hancock RD, et al. N,N′-ethylenedicysteine (EC) and its metal complexes: Synthesis, characterization, crystal structures, and equilibrium constants. Inorg Chem 1996;35:404.
24. Marshall S, Bacote V, Traxinger RR. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. J Biol Chem 1991;266:4706.
25. Wells L, Gao Y, Mahoney JA, et al. Dynamic O-glycosylation of nuclear and cytosolic proteins: Further characterization of the nucleocytoplasmic beta-N-acetylglucosaminidase, O-GlcNAcase. JBiol Chem 2002;277:1755.
26. Pal S, Claffey KP, Cohen HT, et al. Activation of Sp1-mediated vascular permeability factor/vascular endothelial growth factor transcription requires specific interaction with protein kinase C zeta. J Biol Chem 1998;273:26277.
27. Black AR, Black JD, Azizkhan-Clifford J. Sp1 and kruppel-like factor family of transcription factors in cell-growth regulation and cancer. J Cell Physiol 2001;188:143.
28. Pedersen MW, Holm S, Lund EL, et al. Coregulation of glucose uptake and vascular endothelial growth factor (VEGF) in two small-cell lung cancer (SCLC) sublines in vivo and in vitro. Neoplasia 2001;3:80.
29. Hudes GR, Nathan FE, Khater C, et al. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Semin Oncol 1995;22:41.
30. Pienta KJ. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin Oncol 2001;28:3.
31. Horwitz SB. Mechanism of action of taxol. Trends Pharmacol Sci 1992;13:134.
32. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: A novel investigational antimicrotubule agent. J Natl Cancer Inst 1990;82:1247.
33. Lee LF, Schuerer-Maly CC, Lofquist AK, et al. Taxol-dependent transcriptional activation of Il-8 expression in a subset of human ovarian cancer. Cancer Res 1996;56:1303.
34. Duan Z, Feller AJ, Penson RT, et al. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: Analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res 1999;5:3445.
35. Lin-Chao S, Chao CC. Reduced inhibition of DNA synthesis and G(2) arrest during the cell cycle of resistant hela cells in response to cis-diamminedichloroplatinum. J Biomed Sci 1994r;1:131.
36. Bose RN. Biomolecular targets for platinum antitumor drugs. Mini Rev Med Chem 2002;2:103.
37. Stabin M. MIRDOSE: The personal computer software for use in internal dose assessment in nuclear medicine. J Nucl Med 1996;37:538.
38. Bunn PA Jr, Helfrich B, Soriano AF, et al. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin Cancer Res 2001;7:3239.
39. Giraud I, Rapp M, Maurizis JC, et al. Application to a cartilage targeting strategy: Synthesis and in vivo biodistribution of (14)C-labeled quaternary ammonium-glucosamine conjugates. Bioconjug Chem 2000;11:212.